$LQDA

Krepp Sarah sold $149K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 5,245 shares of Liquidia Corp (LQDA) at $28.48 ($0.15M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Oct 14, 2026, 12:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale is modest in size and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

Primary relevance is to shareholders monitoring insider activity; broader market impact is negligible.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions, providing transparency for investors.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Human Resources Officer sold 5,245 shares for $149,377, a routine Form 4 insider sale.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Small sale size ($149k) by a C-suite executive typically has limited impact but can be viewed as a negative signal.

Market effects

Minimal; HR executive sales do not affect the broader biotech sector.

None; the filing is company‑specific.

Low; limited to Liquidia Corp shareholders.

Counterpoint

The sale could be unrelated to confidence and merely a personal liquidity event.

Key entities

  • Liquidia Corp

    Biopharmaceutical company listed on NASDAQ.

  • Krepp Sarah

    Chief Human Resources Officer of Liquidia Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.